Longitudinal relationships between cognitive domains and depression and anxiety symptoms in systemic lupus erythematosus.


Journal

Seminars in arthritis and rheumatism
ISSN: 1532-866X
Titre abrégé: Semin Arthritis Rheum
Pays: United States
ID NLM: 1306053

Informations de publication

Date de publication:
12 2021
Historique:
received: 10 02 2021
revised: 03 09 2021
accepted: 24 09 2021
pubmed: 5 10 2021
medline: 19 3 2022
entrez: 4 10 2021
Statut: ppublish

Résumé

To examine i) the relationship between neuropsychological performance and depression and anxiety over time, and ii) the overlap between classification of cognitive dysfunction, anxiety, and depression in SLE. 301 patients with SLE were included. Cognition was measured using a modified version of the ACR neuropsychological battery; cognitive dysfunction was defined as z-scores ≤-1.5 on ≥2 domains. Depression and anxiety were measured using the Beck Depression Inventory-II and the Beck Anxiety Inventory, respectively. All measures were assessed at baseline, 6, and 12 months. Their relationships were analyzed using Multiple Factor Analysis (MFA). Anxiety and depression and neuropsychological performance were stable across time. Factor analysis identified two dimensions explaining 42.2% of the variance in neuropsychological performance. The first dimension (33.1% of the variance) included primarily complex cognitive tests measuring executive function; verbal, visual, and working memory; and complex processing speed. The second dimension (9.1% of the variance) included primarily measures of simple information processing speed or motor dexterity. Anxiety and depression scores were consistently related to the first cognitive dimension. There was substantial overlap in participants classified with cognitive dysfunction and anxiety and depression. Depression and anxiety symptoms in SLE patients are related to a cognitive dimension incorporating memory, executive function and complex processing speed in a stable manner across one year. Many patients with cognitive dysfunction exhibit clinically significant anxiety and depression. Further research should examine whether cognition improves when anxiety and depression are treated and mechanistic links between anxiety and depression and cognitive dysfunction in SLE.

Identifiants

pubmed: 34607183
pii: S0049-0172(21)00187-6
doi: 10.1016/j.semarthrit.2021.09.008
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1186-1192

Subventions

Organisme : CIHR
Pays : Canada

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest None.

Auteurs

Kathleen S Bingham (KS)

Centre for Mental Health, University Health Network; Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada. Electronic address: kathleen.bingham@uhn.ca.

JuanPablo DiazMartinez (J)

Biostatistics Research Unit, Toronto General Hospital, Toronto, Ontario, Canada.

Robin Green (R)

University Health Network- Toronto Rehabilitation Institute, Toronto, Ontario, Canada.

Maria C Tartaglia (MC)

University of Toronto, Krembil Neurosciences Centre, Toronto, Ontario, Canada.

Lesley Ruttan (L)

University Health Network-Toronto Rehabilitation Institute, Toronto, Ontario, Canada.

Jiandong Su (J)

University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada.

Joan E Wither (JE)

University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada.

Mahta Kakvan (M)

University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada.

Nicole Anderson (N)

University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada.

Dennisse Bonilla (D)

University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada.

May Y Choi (MY)

Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.

Marvin J Fritzler (MJ)

Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.

Dorcas E Beaton (DE)

Institute for Work & Health, Toronto, Ontario, Canada.

Patti Katz (P)

Professor of Medicine and Health Policy, Division of Rheumatology, Department of Medicine, UCSF, Philip R. Lee Institute for Health Policy Studies, USA.

Zahi Touma (Z)

University of Toronto Lupus Clinic, Division of Rheumatology, Department of Medicine; Centre for Prognosis Studies in Rheumatic Diseases, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto Western Hospital, Toronto, Ontario, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH